NEO · NeoGenomics, Inc.

Current Thesis

NeoGenomics is the cleanest momentum expression of the oncology-diagnostics turnaround trade right now. The story an investor is buying is a multi-year reference lab that stalled, churned through leadership, and is now re-accelerating its highest-value mix next-gen sequencing (NGS) and molecular residual disease (MRD) testing into a defensible margin inflection. The Q1 2026 print on April 28, 2026 ($186.7M revenue, +11% YoY, ahead of the $184.53M consensus; clinical revenue +14%; NGS +26% and now roughly one-third of clinical) was the spark, and a raised full-year guide plus a cluster of analyst upgrades turned it into a re-rating. The leg is genuine and accelerating, but at $11.15 (June 12, 2026 close) the name sits in the upper third of its $4.72–$13.74 52-week range after a ~50% advance, RSI ran to ~81 on June 10, and the next hard catalyst is not until the August 5 print. The setup rewards a pullback entry far more than a chase.

Bull Case

• NGS/MRD mix is compounding above the legacy base. Q1 2026 (reported 2026-04-28): NGS revenue +26% YoY vs total revenue +11%, now ~1/3 of clinical revenue. Volumes +6%, average unit price +8% both demand and pricing moving the right way at once.
• RaDaR ST clears a legal overhang and is taking wallet share. Launched 2026-02-25 with detection to 1 ppm after NeoGenomics won summary judgment against Natera (Natera withdrew its appeal in December 2025, leaving the asserted patent claims invalidated). Management reported ~29% of prior RaDaR 1.0 customers have re-ordered RaDaR ST, and 34% of RaDaR ST orders pull in additional NeoGenomics tests early evidence of attach-rate leverage.
• Liquid biopsy reimbursement unlocked. PanTracer LBx received CMS/MolDX (Medicare) coverage in March 2026, opening a $3–5B liquid biopsy TAM; PanTracer Pro and PanTracer Liquid MolDX approval underpinned the guidance raise.
• Guidance raised, margins inflecting. FY2026 revenue guide lifted to $797M–$803M and adjusted EBITDA to $55M–$57M (+27–31% YoY); Q1 adjusted EBITDA +27% YoY. Cash position ~$146M against a $1.45B market cap.
• Analyst upgrade cluster confirms the narrative is going mainstream. Post-Q1: Leerink to Outperform, PT $12→$25 (late April 2026); TD Cowen PT $10→$12; Needham reiterated Buy, PT $15; Benchmark upgraded to Buy at $11. Consensus PT $15.06, range $11–$25, 8–12 Buys and zero Sells a tightening, one-directional revision trend.

Bear Case

• Reference-lab economics are structurally thin. The raised guide implies ~$56M of EBITDA on ~$800M of revenue, near a 7% EBITDA margin. This is a high-volume, low-margin testing business; a few points of reimbursement pressure or volume mix can swing the print.
• The easy turnaround money is already on the tape. Market cap is up ~53% and the stock has roughly tripled off the $4.72 52-week low. Consensus PT of $15.06 is only ~35% from $11.15; the $25 Leerink case requires the MRD/liquid-biopsy ramp to keep beating for several quarters.
• Crowded, better-capitalized competition. Natera's Signatera owns the MRD commercial lead despite losing the patent suit; Guardant, Exact Sciences and Tempus all contest the liquid-biopsy and genomic-profiling markets NeoGenomics is expanding into.
• Pharma services remains the soft segment. Management has flagged pharma-side challenges (Stephens conference), so the clinical engine is carrying the story largely alone.
• High beta, no in-window catalyst. Beta 1.81 means it amplifies any risk-off move, and with no dated event before August 5 the path of least resistance on a tape wobble is mean reversion toward the 50-day.

Setup & Price Structure

Price closed at $11.15 on 2026-06-12 (-2.79% on the day, ~$11.50 after-hours), sitting in the upper third of the $4.72–$13.74 52-week range with the $13.74 high roughly 19% overhead. The advance is post-earnings momentum stacked on an analyst-upgrade cluster: the breakout off the ~$8 shelf came on the April 28 print, and the move extended into early June. RSI pressed ~81 on June 10 a parabolic reading and was cooling toward ~70 by June 12 as the stock printed its first red digestion day. The theme is accelerating and peers are bid, so in this framework strength is the setup and extension alone is not a reason to stand aside. But entry at $11+ into a cooling, recently-parabolic RSI with no fresh near-term catalyst is a chase with compressed reward against the $13.74 cap. The higher-quality entry is a pullback that holds the rising 20-EMA / the ~$9.50–$10 post-Q1 breakout-retest shelf, which would reset risk/reward back above 3:1. This is institutional, revision-driven buying rather than a retail blow-off, so the squeeze-mania trap does not apply the live trap here is paying up for a stretched extension near range highs.

Catalyst Calendar (next 30 days)

• No dated binary catalyst inside the 2026-06-13 → 2026-07-13 window. The RaDaR ST and PanTracer LBx ramps are continuous commercial events, not scheduled prints they show up in volume and attach-rate data, not on a calendar date.
• ~2026-08-05 (est.) Q2 2026 earnings. The next hard binary. This is where the FY2026 guide ($797M–$803M revenue, $55M–$57M adjusted EBITDA) and the NGS growth rate get re-marked. It sits outside the 30-day window, so any near-term move is momentum/flow, not event-driven.
• Ongoing healthcare conference circuit. Mid-cap diagnostics names routinely present at summer investor conferences; any RaDaR ST share or PanTracer reimbursement update could act as an intra-quarter narrative refresh, but nothing is confirmed on a fixed date.

What Would Change Our Mind

• Price/structure break: a weekly close below the ~$9.50–$10 post-Q1 breakout shelf, losing the rising 20-EMA, would mark the momentum leg as broken and argue to stand aside until it rebuilds a base.
• Growth deceleration: at the August 5 print, NGS growth slowing under ~20% or clinical volume growth rolling over would crack the core acceleration thesis.
• Guidance cut: any reduction of the $797M revenue floor or the $55M–$57M adjusted EBITDA range would invalidate the margin-inflection narrative outright.
• Competitive share loss: evidence that RaDaR ST is failing to take MRD share from Natera's Signatera, or that PanTracer is not converting its Medicare coverage into volume, removes the differentiated-product leg.
• Theme saturation: mainstream/CNBC coverage and retail pile-in at the highs would flip the diagnostics-turnaround theme from accelerating to saturated and turn strength into a distribution risk.

Correlation Notes

NEO trades inside the MRD / liquid-biopsy diagnostics complex and tends to move with Natera (NTRA), Guardant Health (GH), Exact Sciences (EXAS) and Tempus (TEM); broad strength across that group is theme confirmation, while a peer breakdown is an early warning that the diagnostics bid is fading. With beta 1.81 it is amplified to the broad risk-on/risk-off tape and to the XBI/IBB biotech complex and small/mid-cap healthcare specifically. As a thin-margin, capital-sensitive growth name it is rate-sensitive: a sharp back-up in yields pressures the multiple regardless of the operational story.

Notes on tradability

The stock trades on a US exchange as a liquid, optionable mid-cap, so the read is directly actionable; position risk should respect the high beta and the absence of a near-term scheduled catalyst.